Beckman Coulter Introduces Cutting-Edge Research Use Only Assays for Neurodegenerative Disease Research
Portfolio Pulse from
Beckman Coulter Diagnostics has launched new Research Use Only (RUO) blood-based biomarker immunoassays to aid neurodegenerative disease research. These assays are available on Beckman Coulter Immunoassay Analyzers.
January 15, 2025 | 1:45 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Beckman Coulter Diagnostics, part of Danaher Corporation, has introduced new RUO assays for neurodegenerative disease research, potentially boosting its diagnostics segment.
The introduction of new RUO assays by Beckman Coulter, a subsidiary of Danaher, could enhance the company's diagnostics segment by providing advanced tools for neurodegenerative disease research. This innovation may lead to increased demand and strengthen Danaher's market position in diagnostics.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 80